Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

VKontakte is in the top 10 generators of global Internet traffic

3/8/23 VKCO

The Amgen announced a quarterly dividend

3/7/23 AMGN

Headhunter reported for 2022

3/7/23 HEAD

Sberbank will bring the number of services based on its own developments to 90%

3/7/23 SBER

Yandex Bank gave up its brokerage license

3/7/23 YNDX

Yandex has created a service for speech synthesis on a single phrase

3/7/23 YNDX

Rusagro board of directors recommends not to pay dividends for 2022

3/7/23 RAGR

Acron completes shaft construction at the Talitsky mine

3/7/23 AKRN

Yandex.Food entered the Uzbekistan market

3/7/23 YNDX

Detsky Mir became a co-owner of the Russian business of Finnish Reima

3/7/23 DSKY